AstraZeneca's Antibody Drug Evusheld Can Help Fight Omicron Variant

AstraZeneca, the British-Swedish drugmaker's antibody medication 'Evusheld,' was found to be effective against the Omicron COVID-19 variant.

The finding is based on alive virus neutralization data from University College Oxford, UK, and Washington University School of Medicine, US, which showed that Evusheld (tixagevimab co-packaged with cilgavimab) retains neutralization activity against the Omicron SARS-CoV-2 variant (B.1.1.529), the company said in a statement.

Study Says Omicron Has a Greater Capacity to Bind With Human Cells
Mutations in Omicron variant bond with human cells far more efficiently than previous strains revealed a study led by an Indian-origin researcher.

While the Omicron variant was not in circulation during the Evusheld clinical trials, the company added that it is continuing to collect further data to better understand the implications of this data in clinical practice. The findings from both studies were posted online on preprint server bioRxiv, and not peer-reviewed yet.

In early December, the US Food and Drug Administration granted emergency use authorisation (EUA) to Evusheld -- an injectable monoclonal antibody cocktail of tixagevimab co-packaged with cilgavimab -- for Covid-19 among people with weakened immune systems. It is the first antibody treatment against Covid-19 that has won an EUA from the drug regulator.

According to the researchers, the levels of neutralizing potency are within the range of titres found in individuals who have been previously infected with and recovered naturally from Covid-19.

Maharashtra Reports 23 Omicron Cases
Maharashtra has reported the highest spike of Omicron cases, 23, so far, taking the tally to 88, said health officials.

The data were generated from laboratory testing using actual live virus isolated from individuals who contracted the Omicron variant of Covid-19 -- considered a 'gold standard' for antibody neutralization studies.

"Consistent data across three independent studies now provide confidence that Evusheld -- a combination of two highly potent antibodies -- retains neutralising activity against the Omicron variant at a level that will continue to provide benefit to patients," said Mene Pangalos, Executive Vice-President, BioPharmaceuticals R&D, AstraZeneca.

COVID-19: Oxford-AstraZeneca Begins Work on Omicron-Targeted Vaccine
The pharma giant AstraZeneca and Oxford University have come together to develop a COVID-19 vaccine that specifically targets the Omicron variant.

"Evusheld is now available to help protect vulnerable populations, such as the immunocompromised, who are unable to mount an adequate response to vaccination and remain at high-risk of Covid-19," Pangalos added.

Besides the US, Evusheld has also won approval from drug authorities in other countries, including France and Italy.

Omicron Becomes Dominant Variant in The US
Omicron has become the dominant Covid-19 variant in the US. Get vaccinated and boosted before travelling or attending any gatherings, wear your mask even in indoor settings and practice physical distancing.

Source-IANS